Contributions
Abstract: PB1589
Type: Publication Only
Session title: Infections in hematology (incl. supportive care/therapy)
Background
The risk of acquiring both hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in patients with cancer has been documented. Risk of parenteral transmission of viral hepatitis has been well recognized, especially due to blood product transfusions.
Aims
Retrospectively collecting baseline and follow up data to determine the rate of hepatitis B and C infection in children with ALL. To determine the extent of liver toxicity in patients infected with hepatitis B and C compared to those who do not acquire the infections, and to recognize any relation between seroconversion and different variables.
Methods
The duration of the data collection and analysis of the study was from August 2018 till October 2019. A retrospective study included 92 children with Acute Lymphoblastic Leukemia diagnosed consecutively in a 2-year period; 2015-2016 at Oncology Unit in Children Welfare Teaching Hospital. Demographic information, treatment details, vaccination history and baseline hepatitis screen were documented. Follow up data during ALL therapy regarding the mass of blood products received by the patients, regular assessment of liver enzymes and bilirubin as well as hepatitis B and C testing was done every 3 months. Documentation of any interruption or omission of chemotherapy related to liver dysfunction and Neutropenia. Detection of seroconversion for HBV and HCV by serology and viral load if serology was positive, all taken in a chronological manner.
Results
At the time of diagnosis, all patients were serologically negative from HBV and HCV. During the follow up period, there were 19 (20.6%) patients infected with hepatitis by serological method; 18 with hepatitis C and one with hepatitis B. there was no significant correlation between seroconversion with hepatitis and liver dysfunction, blood product transfusions more than 10 times, chemotherapy delay due to liver dysfunction and risk group. The mean duration from date of diagnosis till date of last follow up was 43.7 months (range 28.6-56.2 months), while the duration from date of diagnosis till seroconversion with hepatitis was 44.2 months (range 6.9-56.4 months).
Conclusion
Low incidence of HBV and high incidence of HCV was noticed in this group of patients, there was no direct significant correlation to blood product transfusions. Primary and secondary prevention from infection as a WHO recommendation and Continuous regular screening for HCV for several years after discontinuation of chemotherapy to detect dormant infection is of paramount role.
Keyword(s): Children, Hepatitis, Leukemia, Transfusion
Abstract: PB1589
Type: Publication Only
Session title: Infections in hematology (incl. supportive care/therapy)
Background
The risk of acquiring both hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in patients with cancer has been documented. Risk of parenteral transmission of viral hepatitis has been well recognized, especially due to blood product transfusions.
Aims
Retrospectively collecting baseline and follow up data to determine the rate of hepatitis B and C infection in children with ALL. To determine the extent of liver toxicity in patients infected with hepatitis B and C compared to those who do not acquire the infections, and to recognize any relation between seroconversion and different variables.
Methods
The duration of the data collection and analysis of the study was from August 2018 till October 2019. A retrospective study included 92 children with Acute Lymphoblastic Leukemia diagnosed consecutively in a 2-year period; 2015-2016 at Oncology Unit in Children Welfare Teaching Hospital. Demographic information, treatment details, vaccination history and baseline hepatitis screen were documented. Follow up data during ALL therapy regarding the mass of blood products received by the patients, regular assessment of liver enzymes and bilirubin as well as hepatitis B and C testing was done every 3 months. Documentation of any interruption or omission of chemotherapy related to liver dysfunction and Neutropenia. Detection of seroconversion for HBV and HCV by serology and viral load if serology was positive, all taken in a chronological manner.
Results
At the time of diagnosis, all patients were serologically negative from HBV and HCV. During the follow up period, there were 19 (20.6%) patients infected with hepatitis by serological method; 18 with hepatitis C and one with hepatitis B. there was no significant correlation between seroconversion with hepatitis and liver dysfunction, blood product transfusions more than 10 times, chemotherapy delay due to liver dysfunction and risk group. The mean duration from date of diagnosis till date of last follow up was 43.7 months (range 28.6-56.2 months), while the duration from date of diagnosis till seroconversion with hepatitis was 44.2 months (range 6.9-56.4 months).
Conclusion
Low incidence of HBV and high incidence of HCV was noticed in this group of patients, there was no direct significant correlation to blood product transfusions. Primary and secondary prevention from infection as a WHO recommendation and Continuous regular screening for HCV for several years after discontinuation of chemotherapy to detect dormant infection is of paramount role.
Keyword(s): Children, Hepatitis, Leukemia, Transfusion